ClinicalTrials.gg
RecruitingNCT06451575Updated Jun 11, 2024

Thrombophilia and Thrombosis in Behçet's Disease

An observational study in Behçet Disease, sponsored by Ataturk University. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-11.

Sponsored by Ataturk University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Behcet Syndrome with a site in Turkey — 9 open to participants now, 10 under way, 3 of them phase 3. Behcet Syndrome · Turkey.

Planned enrollment
2nd of 13
200 · median 60
Started
2023
with 1 other
Observational
14 of 30
4 open now
Registered
25th of 30
by date
Lead sponsor
2 of 30
Ataturk University

Among the 30 studies in Behcet Syndrome with a site in Turkey, this one is the 2nd largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2023, is one of 14 observational ones, and was the 25th registered.

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.

Browse Behcet Syndrome studies →

Open to participants now

9 of the 30 studies in Behcet Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Behcet Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

Behçet's disease (BD) is a systemic vasculitis of unknown cause, affecting mainly young adults. Vasculopathy has been reported in 16.8-51.5% of cases. Genetic, infectious factors, environmental factors, presence of autoantibodies, endothelial pathologies and hypercoagulability are responsible for the etiopathogenesis of BD. The main involvements responsible for morbidity and mortality in Behçet's disease are ocular, major cardiovascular and neurological involvements. Although there is an increased thrombotic risk in the etiopathogenesis of Behçet's disease, the cellular and molecular mechanisms are not fully understood. Although endothelial dysfunction due to inflammation has been shown to be the primary cause of vascular damage in Behçet's disease, some clinical evidence suggests that hypercoagulable states also contribute to thrombosis. The most common form of vascular involvement in Behçet's disease is deep vein thrombosis in the lower extremities. Arterial occlusion mostly affects the subclavian and pulmonary arteries. Although arterial involvement is rarer than venous involvement in Behçet's disease, morbidity and mortality are higher than venous involvement.

Although an increased thrombotic risk is mentioned in the etiopathogenesis of Behçet's disease, it is still controversial whether vasculitis or susceptibility to hypercoagulability plays a role in the pathogenesis of venous thrombosis. In addition, there are very few studies in the literature in which all thrombophilic parameters were analysed. Again, there is no recent study on this subject. The aim of our study is to determine the risk of hypercoagulability in Behçet's disease patients with vascular involvement, which has a highly mortal course.

Read the detailed description

The study was planned as a prospective case control study. The study will be conducted on 100 Behçet's patients aged 18-70 years who were diagnosed with Behçet's disease according to the International Behçet's diagnostic criteria and 100 healthy controls similar in age and gender who applied to Atatürk University Faculty of Medicine Dermatology outpatient clinic between June 2023 and September 2024. Routine clinical evaluations of all patients will be performed. Demographic characteristics (age, gender), clinical features of the disease and medications used will be recorded. Patients will be included in the study after the relevant department consultations for system involvement. Skin and mucous membrane findings seen in the last 1 month will be recorded. Blood samples will be taken from all participants and analysed in the Genetics laboratory of our hospital. DNA isolation will be performed with DNA isolation kit from peripheral blood in EDTA tube taken from patients during routine examinations. DNA samples will be stored at -20 degrees Celsius until the time of the study. After collecting the targeted number of samples, Factor II G20210A, Factor V Leiden G1691A, MTHFR (Methylene Tetra Hydro Folate Reductase) C677T, MTHFR A1298C, Factor XIII V34L, PAI (Plasminogen Activator Inhibitor-1) 4G/5G SNP (single nucleotide polymorphisms) analyses will be performed with the thrombophilia panel kit. This analysis will be performed by fragment analysis method on the ABI 3130 Genetic analyser device in the Medical Genetics Laboratory. Firstly, PCR study will be performed with the thrombophilia panel kit, the plate with patient DNA will be loaded into the capillary electrophoresis device and the analyses will be interpreted and finalised with GeneMapper software.

03

Conditions studied

  • Behçet Disease

Keywords

  • thrombosis
  • thrombophilia
  • Behcet's disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

100 patients with Behçet's disease aged 18-70 years and 100 age- and sex-matched healthy controls

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-70 years old
  2. Patients who fulfil the international diagnostic criteria for Behçet's disease
  3. Those who accepted the consent form

Exclusion criteria

Exclusion Criteria:

  1. Those under 18 years of age
  2. accompanied by another inflammatory dermatological disease
  3. Pregnancy and breastfeeding
  4. Those who use drugs that increase the tendency to thrombosis -
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cases with Behcet's disease

    Behcet's disease

    Diagnostic Test: Blood collection

  • healthy individuals

    Healthy control group

    Diagnostic Test: Blood collection

Interventions

  • Diagnostic testBlood collection

    Blood collection

06

What researchers measure

Primary outcomes

  1. Faktor II G20210A kit

    Faktor II G20210A at 200 participants

    Time frame: 15 months

  2. Faktor V Leiden kit

    Faktor V Leiden at 200 participants

    Time frame: 15 months

  3. G1691A kit

    G1691A at 200 participants

    Time frame: 15 months

  4. MTHFR (Methylene Tetra Hydro Folate Reductase) kit

    MTHFR (Methylene Tetra Hydro Folate Reductase) at 200 participants

    Time frame: 15 months

  5. C677T kit

    C677T at 200 participants

    Time frame: 15 months

  6. Factor XIII kit

    Factor XIII at 200 participants

    Time frame: 15 months

  7. With DNA isolation kit

    PAI (Plasminogen Activator Inhibitor-1) at 200 participants

    Time frame: 15 months

07

Study locations

1 of 1 sites recruiting
  • Erdal Pala
    Erzurum, Üniversite Mahallesi 25240, Turkey
    Recruiting
    • ERDAL PALA · Contacterdalpala2525@gmail.com · +95383753661
    • Zeynep karaca Ural · Sub investigator
    • Çiğdem Yüca Kahraman · Sub investigator
    • Ümit Arslan · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Sep 2024, 15 months after the start.

Of 21 observational studies under Behcet Syndrome, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 81. This study's planned 15 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2024
First posted
Jun 11, 2024
StartActual
Jun 1, 2023
Primary completionEst.
Sep 1, 2024
CompletionEst.
Sep 1, 2024
Last update
Jun 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06451575
Lead sponsor
Ataturk University
Responsible party
Erdal Pala (assistant professor doctor, Ataturk University) — Principal investigator
First posted
Jun 11, 2024
Start date
Jun 1, 2023
Primary completion
Sep 1, 2024 (estimated)
Completion
Sep 1, 2024 (estimated)
Last update
Jun 11, 2024

Study contacts

ERDAL PALA
Contact
erdal.pala@atauni.edu.tr
+95383753661
ERDAL PALA
principal investigator · Ataturk University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion